Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation
The <i>KRAS</i> gene is mutated in approximately 45% of colorectal cancer patients. There are currently very few targeted treatments or therapies equipped to directly inhibit <i>KRAS</i> due to its unusual structural intricacies. Erlotinib, an EGFR inhibitor, has previously b...
| Published in: | Current Issues in Molecular Biology |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-07-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/46/7/447 |